Effect of Common barberry extract in type 2 diabetic patients

Study of the effect of extract of Common barberry (Berberis vulgaris L.) on oxidative stress in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011221412N3

Enrollment

Registered

2016-05-22

Start date

2015-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: intervention group 1: patients with type 2 diabetes (24 women) which will use common diabetes drugs. Intervention 2: intervention group 2: patients with type 2 diabetes (24 women) that

Treatment - Drugs

intervention group 1: patients with type 2 diabetes (24 women) which will use common diabetes drugs.

intervention group 2: patients with type 2 diabetes (24 women) that ingest 5cc of common barberry extract during 8 weeks.

control group: 24 women without type 2 diabetes which will not undergo any treatment

Eligibility

Sex/Gender

Female

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: female gender over the age of 50 years old; HbA1c levels equal or less than 10%; common diabetes drugs usage (Metformin and Glibenclamide); patients with triglyceride. Exclusion criteria: patients with cardiovascular; renal; liver; thyroid diseases; infections; allergies; angina; the regular use of NSAIDs (Non-Steroid Anti Inflammatory Drugs); warfarin; alcohol; herbal tea; dietary supplements; insulin injection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Plasma Glucose. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Triglycerides. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum superoxide dismutase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Nitric Oxide. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum glutamic-pyruvic transaminase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum glutamic- oxaloacetic transaminase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;High-density lipoprotein. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Low-density lipoprotein. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).	—

Measure

Time frame

Fasting Plasma Glucose. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Triglycerides. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum superoxide dismutase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Nitric Oxide. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum glutamic-pyruvic transaminase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Serum glutamic- oxaloacetic transaminase. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;High-density lipoprotein. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).;Low-density lipoprotein. Timepoint: After and before 8 weeks of continuous treatment. Method of measurement: Blood test by using a Pars Azmoon biochemical kit (Pars Azmoon Co., Tehran, Iran).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamid Kalalian Moghadam

Shahroud University of Medical Sciences

h.kalalian@shmu.ac.ir+98 23 3239 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026